RenovoRx Inc. unveils investor presentation highlighting RenovoCath commercialization and clinical progress

Reuters01-20

<a href="https://laohu8.com/S/RNXT">RenovoRx Inc</a>. unveils investor presentation highlighting RenovoCath commercialization and clinical progress

RenovoRx Inc. has provided an update on the commercialization of its FDA-cleared RenovoCath® device, reporting approximately $900,000 in revenue through the third quarter of 2025. The company has expanded its customer base from five to fourteen cancer centers, with quotes delivered to an additional ten centers and ongoing discussions with dozens more. RenovoRx is targeting an initial potential peak annual U.S. revenue opportunity of around $400 million for RenovoCath as a stand-alone device, with opportunities to expand into additional applications. Enrollment in its ongoing clinical study is expected to be completed in the first half of 2026, with final data anticipated in 2027. The company’s proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform, enabled by RenovoCath, is being positioned to address challenges in delivering therapy to tumors with poor blood supply, such as pancreatic cancer. You can access the full presentation through the link below. https://renovorx.com/for-clinicia

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on January 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604013275?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-20 00:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604013275","market":"nz","top_or_hot":-1,"title":"RenovoRx Inc. unveils investor presentation highlighting RenovoCath commercialization and clinical progress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RNXT\">RenovoRx Inc</a>. unveils investor presentation highlighting RenovoCath commercialization and clinical progress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        RenovoRx Inc. has provided an update on the commercialization of its FDA-cleared RenovoCath® device, reporting approximately $900,000 in revenue through the third quarter of 2025. The company has expanded its customer base from five to fourteen cancer centers, with quotes delivered to an additional ten centers and ongoing discussions with dozens more. RenovoRx is targeting an initial potential peak annual U.S. revenue opportunity of around $400 million for RenovoCath as a stand-alone device, with opportunities to expand into additional applications. Enrollment in its ongoing clinical study is expected to be completed in the first half of 2026, with final data anticipated in 2027. The company’s proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform, enabled by RenovoCath, is being positioned to address challenges in delivering therapy to tumors with poor blood supply, such as pancreatic cancer. You can access the full presentation through the link below. https://renovorx.com/for-clinicia\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on January 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RenovoRx Inc. unveils investor presentation highlighting RenovoCath commercialization and clinical progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRenovoRx Inc. unveils investor presentation highlighting RenovoCath commercialization and clinical progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-20 00:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RNXT\">RenovoRx Inc</a>. unveils investor presentation highlighting RenovoCath commercialization and clinical progress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        RenovoRx Inc. has provided an update on the commercialization of its FDA-cleared RenovoCath® device, reporting approximately $900,000 in revenue through the third quarter of 2025. The company has expanded its customer base from five to fourteen cancer centers, with quotes delivered to an additional ten centers and ongoing discussions with dozens more. RenovoRx is targeting an initial potential peak annual U.S. revenue opportunity of around $400 million for RenovoCath as a stand-alone device, with opportunities to expand into additional applications. Enrollment in its ongoing clinical study is expected to be completed in the first half of 2026, with final data anticipated in 2027. The company’s proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform, enabled by RenovoCath, is being positioned to address challenges in delivering therapy to tumors with poor blood supply, such as pancreatic cancer. You can access the full presentation through the link below. https://renovorx.com/for-clinicia\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on January 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nNDL8HMCLc:1","article_id":"2604013275","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604013275","pubTimestamp":1768841409,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on January 19, 2026, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","RNXT":"RenovoRx Inc"},"translate_title":"RenovoRx Inc.发布投资者演示文稿，重点介绍RenovoCath的商业化和临床进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNXT":0.9},"content_text":"RenovoRx Inc. unveils investor presentation highlighting RenovoCath commercialization and clinical progress\n    \n\n        RenovoRx Inc. has provided an update on the commercialization of its FDA-cleared RenovoCath® device, reporting approximately $900,000 in revenue through the third quarter of 2025. The company has expanded its customer base from five to fourteen cancer centers, with quotes delivered to an additional ten centers and ongoing discussions with dozens more. RenovoRx is targeting an initial potential peak annual U.S. revenue opportunity of around $400 million for RenovoCath as a stand-alone device, with opportunities to expand into additional applications. Enrollment in its ongoing clinical study is expected to be completed in the first half of 2026, with final data anticipated in 2027. The company’s proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform, enabled by RenovoCath, is being positioned to address challenges in delivering therapy to tumors with poor blood supply, such as pancreatic cancer. You can access the full presentation through the link below. https://renovorx.com/for-clinicia\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on January 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604013275","isCrawlerRequest":true}